Phase I multiple ascending dose trial of BAL 30072 in healthy volunteers.

Trial Profile

Phase I multiple ascending dose trial of BAL 30072 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2013

At a glance

  • Drugs BAL 30072 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 25 Jun 2013 Maximum tolerated dose has been reached (dose-limiting factor was reversible elevated liver enzyme levels), according to Basilea Pharmaceutica media release.
    • 07 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top